The clinical development of EGFR inhibitors in NSCLC started before the discovery of EGFR mutations, therefore initial studies with Gefitinib and Erlotinib were conducted in unselected patients in both pretreated [52–54] and in treatment-naïve patients in combination with standard chemotherapy [55–58]. Here, EGFR is linked to non-small cell lung carcinoma.